Patients with frequent migraines and/or who experience functional disability need preventative migraine treatment. However, studies have shown that of the 38% of patients who stand to benefit from prophylactic therapy, only 3-13% actually receive it. Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) are under clinical investigation and constitute a new prophylactic migraine therapy class. New therapies and increased clinician attention when individualizing treatment plans continue to be vital as new agents emerge and when maximizing patient function.
This activity is designed for clinicians involved in the care and treatment of patients with migraine pain.
Upon completion of this activity, participants will be able to:
Illustrate how to factor multiple patient-specific characteristics into the treatment plan when managing migraines
Examine and discuss the emerging science associated with CGRP mAbs and their role in migraine prevention
Highlight strategies and tools to assess the impact of migraine on daily functioning and quality of life in order to generate a more personalized and inclusive treatment plan
Conflict Of Interest Disclosure Policy
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
David Dodick, MD, FAHS, FRCPC, FACP Mayo Clinic Phoenix, AZ
Dr. Dodick discloses the following: Consulting Agreements: Alder BioPharmaceuticals Inc.; Allergan; Amgen; Autonomic Technologies; Boston Scientific; Dr. Reddy’s Laboratories Ltd.; Eli Lilly and Company; eNeura, Inc.; INSYS Therapeutics; Teva Pharmaceutical Industries Ltd.; Trigemina, Inc.; Xenon Pharmaceuticals Inc, Zosano Patent Holder: Allergan PREEMPT injection paradigm Stockholder: EPIEN Medical, Inc.; Second Opinion, Inc.; Xalan, LLC/GBS Ventures
Deborah I. Friedman, MD, MPH, FAHS University of Texas Southwestern Medical Center Dallas, TX
Dr. Friedman discloses the following: Advisor: Alder BioPharmaceuticals, Avanir, Supernus, Teva, Zosano Sources of Funding for Research and/or Clinical Trials: Autonomic Technologies, Inc., Merck Consulting Agreements: Allergan, Avanir, Eli Lilly Speakers' Bureau: Allergan, Avanir, Teva
Stewart J. Tepper, MD, FAHS Geisel School of Medicine at Dartmouth Hanover, NH
Dr. Tepper discloses the following: Advisor: Acorda, Alder, Allergan, Amgen, ATI, Avanir, Dr. Reddy’s Laboratories Ltd, Electrocore, eNeura, Kimberly-Clark, Pernix, Pfizer, Scion Neurostim, Supernus, Teva, Zosano Sources of Funding for Research: Alder, Allergan, Amgen, ATI, Avanir, Electrocore, eNeura, Scion Neurostim, Teva, Zosano Stockholder: ATI
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
To obtain credit, a score of 60% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact: Laurie Novoryta Senior Program Manager, ACHL Lnovoryta@achlcme.org